{
    "nctId": "NCT02023359",
    "briefTitle": "Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer",
    "officialTitle": "Observational Study of Everolimus in Combination With Exemestane in Postmenopausal Patients With Hormone Receptor-positive, HER 2-negative Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 7,
    "primaryOutcomeMeasure": "Adverse Events",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal women with HR-positive, HER2-negative advanced breast cancer who are treated with everolimus and exemestane according to the approved Summary of Product Characteristics (SmPC).\n* Patients who started treatment after approval of this indication but before the initiation of this study can be retrospectively included, provided that they have systematically been assessed for adverse events.\n* The decision to treat the patient with everolimus and exemestane must be independent of the patient's participation in the study.\n* The patient must provide signed Informed Consent before any data can be captured.\n\nExclusion Criteria:\n\n- No formal exclusion criteria",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}